| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88131f4331161b0af4fe46003e44f2a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-555 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate |
2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b1d4df82545d707ca2f7e7b199ee7dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_967551b13f3a75d7ad6f62792a07954e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80d65de5e0ce2144bceb5028defc967d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2410017e0ddfa0f3f0bf1d6294803de3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c55691d68964b95ffe33ee4b634301f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22a50bb524cfcff6b063bbfb69323aa |
| publicationDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101818901-B1 |
| titleOfInvention |
Inactivated vaccine composition of Actinobacillus pleuroneumoniae inactivated bacterin and N or C fragments of Actinobacillus pleuroneumniae ApxIA, ApxIIA, ApxIIIA inactivated toxin |
| abstract |
The present invention relates to a pharmaceutical composition comprising an N and C terminus of the recombinant ApxIA of Pork Pleuropneumoniae, N and C terminus of ApxIIA, N and C terminus antigens of ApxIIIA, and a porcine pleuropneumoniae type 2 and 5 type of formalin- To a vaccine composition for the prevention or treatment of swine pneumonia. The present invention is a vector developed to increase the secretion of the N and C termini of ApxIA derived from the pleural fluid of pigs, the N and C termini of ApxIIA, and the N and C terminal antigens of ApxIIIA. Escherichia coli E. coli ), isolating and purifying each protein from the transformed expressing Escherichia coli, and inoculating a mixture of serotype 2 and 5 -formylated fluorophilic cells derived from porcine pleural fluid pneumonia, It has been confirmed that it is effectively resistant to sex immunity and to the toxicity of pig pleuritic pneumonia. Therefore, the recombinant antigen and the inactivated cell mixture of the present invention is expected to be useful as a safe, economical and easy-to-inoculate vaccine for the prevention and treatment of swine pneumonia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190014265-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200076551-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022023819-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102018707-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210061741-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220056701-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102514051-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102336245-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102228308-B1 |
| priorityDate |
2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |